Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.
Type:
Grant
Filed:
July 1, 2003
Date of Patent:
February 6, 2007
Assignees:
Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
Abstract: The differential display method was used to search for a gene whose expression level in eosinophils collected from patients with atopic dermatitis differs in the exacerbation stage and in the remission stage. As a result, gene “2090-05” showing a significant increase in expression in eosinophils of patients in the remission stage was isolated. This gene is usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.
Type:
Grant
Filed:
September 21, 2001
Date of Patent:
December 12, 2006
Assignees:
Japan as represented by General Director of Agency of National Center for Child Health and Development, Eisai Co., Ltd., Genox Research, Inc.
Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
Type:
Grant
Filed:
June 27, 2003
Date of Patent:
October 3, 2006
Assignees:
Genox Research, Inc., Japan as Represented by General Director of Agency of National Center For Child Health & Development
Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
Type:
Application
Filed:
June 27, 2003
Publication date:
October 28, 2004
Applicants:
Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
Abstract: B1799 gene, whose expression level increases significantly in the patient group, was successfully identified by screening for a gene which shows difference in expression in blood collected from multiple healthy subjects and patients of allergic diseases employing the differential display method. The gene expression level is specifically high in T cells and increased due to T cell activation. This gene can be used in testing for allergic diseases and also in screening for therapeutic agents for allergic diseases.
Type:
Application
Filed:
April 3, 2003
Publication date:
December 4, 2003
Applicants:
Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
Abstract: The SOCS3 gene has been identified as a gene whose expression level in T cells of patients with an atopic disorder is significantly higher than that of the normal healthy subjects. The present inventors found that this gene can be used in testing for allergic diseases and in screening for therapeutic agents. The present invention enables screening for compounds useful in the treatment of allergic diseases.
Type:
Application
Filed:
February 27, 2003
Publication date:
November 27, 2003
Applicants:
Genox Research, Inc., Japan as represented by general director of agency of National Center for Child Health & Development